NCT01524536View on ClinicalTrials.gov

Steroid Treatment for Hypereosinophilic Syndrome

PHASE4CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

February 16, 2012

Primary Completion Date

December 10, 2020

Study Completion Date

December 10, 2020

Conditions
EosinophiliaHypereosinophilic SyndromeLeukocyte DisorderHematologic Diseases
Interventions
DRUG

prednisone

Glucocorticoids (GC) are considered the first- line therapy for hypereosinophilic syndrome.

Trial Locations (1)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT01524536 - Steroid Treatment for Hypereosinophilic Syndrome | Biotech Hunter | Biotech Hunter